Safety and efficacy of denosumab in children with osteogenesis imperfecta - a first prospective trial

OBJECTIVES: Osteogenesis imperfecta (OI) is a rare hereditary disease leading to bone fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been approved for osteoporosis treatment in adults. Aim of this study was a 48-week, open-label, pilot study of the safety and eff...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Musculoskelet Neuronal Interact
मुख्य लेखकों: Hoyer-Kuhn, H., Franklin, J., Allo, G., Kron, M., Netzer, C., Eysel, P., Hero, B., Schoenau, E., Semler, O.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: International Society of Musculoskeletal and Neuronal Interactions 2016
विषय:
Original Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5089451/
https://ncbi.nlm.nih.gov/pubmed/26944820
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन